These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

A human-derived, ultra-long-acting GLP-1 injection independently researched and developed by Innogen, a Shanghai-based ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Learn about the financial strain caused by the skyrocketing demand and costs of GLP-1 drugs, and how health plans and providers are struggling to balance it.

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss drugs, but the jury's out on w ...

NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous ...